Takara Bio is a leading provider of innovative life science solutions supporting genomics, cell biology, gene therapy, and translational research. Following its recent acquisition of Curio Bioscience, Takara Bio has expanded its spatial biology portfolio, enabling researchers to gain deeper insights into gene expression within tissue architecture and accelerate discoveries in complex biological systems. Alongside its broad range of research and GMP-grade products, Takara Bio offers customization and OEM services through its European hub.
These capabilities allow partners to tailor products to specific requirements, supporting the development and commercialization of differentiated solutions while benefiting from local expertise, manufacturing, and technical support. The company’s portfolio includes industry-leading technologies such as PrimeSTAR® PCR enzymes, In-Fusion® seamless cloning systems, SMART-Seq® solutions for single-cell and low-input RNA sequencing, RetroNectin® for cell and gene therapy workflows, and advanced stem cell culture systems. Combined with Curio’s spatial genomics technologies and Takara Bio’s European customization and OEM capabilities, these solutions help researchers and industry partners advance innovation from discovery through clinical application.
